GLOBUS MEDICAL, INC. financials

  1. Home
  2. Financials
  3. GMED
GMED CIK 0001237831

Source: EDGAR filings · Built 2026-06-02T03:08:44Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow 588.43M 404.21M 164.31M 104.42M 219.38M 135.13M
EBITDA 756.66M 419.38M 278.67M 296.20M 241.82M 174.31M
Working Capital 1.63B 1.32B 1.52B 824.14M 724.35M 700.97M
Net Debt -406.72M -246.72M 53.92M -144.46M -188.02M -234.60M
Gross Margin 67.41% 58.90% 65.05% 74.22% 75.03% 72.44%
Operating Margin 16.33% 6.59% 8.49% 22.29% 17.95% 14.12%
Net Margin 18.30% 4.09% 7.83% 18.59% 15.57% 12.96%
Return on Equity (ROE) 11.76% 2.47% 3.07% 10.30% 8.57% 6.79%
Return on Assets (ROA) 10.14% 1.96% 2.42% 9.16% 7.62% 6.09%
Current Ratio 4.26× 2.54× 4.88× 6.18× 6.17× 6.80×
Debt-to-Equity 0.03× 0.13× 0.13× 0.00× 0.00× 0.00×
Effective Tax Rate 11.11% 14.69% 25.71% 21.75% 17.30% 18.76%
Cash Conversion Ratio 1.40× 5.06× 1.98× 0.94× 1.85× 1.94×
Accruals Ratio -0.04× -0.08× -0.02× 0.01× -0.06× -0.06×
SBC % of Revenue 1.69% 2.15% 3.36% 3.21% 3.19% 3.43%
CapEx Coverage 4.57× 4.47× 3.08× 2.41× 4.86× 3.12×
Free Cash Flow Per Share $4.29 $2.93 $1.43 $1.02 $2.12 $1.34

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
P/E Trailing (Diluted) 22.27× 110.28× 49.80× 40.15× 50.14× 64.57×
P/FCF 20.34× 28.21× 37.18× 73.01× 34.10× 48.73×
FCF Yield 4.92% 3.54% 2.69% 1.37% 2.93% 2.05%
EV / EBITDA 15.07× 26.54× 26.08× 24.66× 29.54× 35.99×
P/S 4.02× 4.52× 4.60× 7.28× 7.65× 8.25×
P/B 2.58× 2.72× 1.80× 4.03× 4.21× 4.32×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenues 2.94B 2.52B 1.57B 1.02B 958.10M 789.04M
Cost of Goods and Services Sold 957.80M 1.04B 548.17M 263.73M 239.22M 217.46M
Gross Profit — — 1.02B 759.12M 718.88M 571.58M
Research and Development Expense 147.25M 163.75M 124.01M 73.02M 97.35M 84.52M
Selling, General and Administrative Expense 1.18B 981.36M 643.84M 432.12M 408.15M 354.76M
Operating Expenses — — 887.16M 531.17M 546.93M 460.15M
Operating Income (Loss) 479.82M 165.99M 133.14M 227.95M 171.95M 111.43M
Income Tax Expense (Benefit) 67.20M 17.74M 42.52M 52.85M 31.22M 23.61M
Net Income (Loss) Attributable to Parent 537.87M 102.98M 122.87M 190.17M 149.19M 102.28M
Earnings Per Share, Basic $3.98 $0.76 $1.09 $1.89 $1.48 $1.04
Weighted Average Number of Shares Outstanding, Basic 135.22M 135.73M 113.09M 100.47M 100.73M 98.58M
Earnings Per Share, Diluted $3.92 $0.75 $1.07 $1.85 $1.44 $1.01
Weighted Average Number of Shares Outstanding, Diluted 137.06M 137.86M 114.63M 102.64M 103.62M 100.97M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 526.16M 784.44M — — — —
Assets, Current 2.13B 2.18B 1.92B 983.34M 864.52M 821.76M
Assets 5.30B 5.25B 5.09B 2.08B 1.96B 1.68B
Liabilities, Current 498.50M 855.91M 392.35M 159.20M 140.16M 120.79M
Liabilities 729.51M 1.07B 1.09B 229.75M 215.88M 173.19M
Stockholders' Equity Attributable to Parent 4.57B 4.18B 4.00B 1.85B 1.74B 1.51B

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities 753.45M 520.64M 243.50M 178.47M 276.27M 198.79M
Payments to Acquire Property, Plant, and Equipment 164.68M 115.43M 78.27M 74.05M 56.90M 63.66M
Net Cash Provided by (Used in) Investing Activities -355.01M -176.05M 302.97M -110.36M -375.94M -117.32M
Payments for Repurchase of Common Stock 300.45M 85.79M 225.56M 144.49M — 104.67M
Net Cash Provided by (Used in) Financing Activities -679.16M -27.70M -231.82M -109.96M 54.15M -38.66M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (GMED CIK 0001237831), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

ILMN

Illumina, Inc.

RZLV

Rezolve AI plc

BFC

Bank First Corp